ONCS to Host Webinar to Provide Update on 03/23

Final day to submit questions for the webinar next Monday. Here are the questions I tweeted to them:

- Will you announce interim data from the expansion trial and when do you expect final data from that trial?

- What is the hold up with the P2b combo trial? PR said Q1 for enrollment.

- How many patients in P2b?

- With good interim P2b data, will you apply for breakthrough designation /fast-tracking/pivotal trial?

- Is a reverse split and up-listing to a nat'l exchange currently considered a corporate objective for the company?

Good news seems like it's too much to hope for. I'm hoping that Punit will put in a good showing though. Hopefully a more casual presentation and hand picked questions will enable him to shine through on Monday. I have off from work, so I'm excited to sit around and listen, even if it's just so I can make smart aleck comments afterwards :0)

I woke up just in time to hear the legal mumbojumbo at the beginning. That being said, I need to make some coffee and my computer speakers are pathetic and there's no volume control on their webinar program. I had to get headphones in order to actually hear. Nothing to report in the first 10 minutes I hope.

Expecting data readouts from IL-12 trials by Q4...

University of California San Fransisco... Currently in the process of getting Review Board approval for phase II studies.

Pilot study summary for Triple Negative Breast Cancer with Stanford.

Okay. Financial update... this is something I might be able to follow.

They want to partner and license with somebody to get their products out there... Non-dilutive funding... I want a pony, too.
Punit restated that they have money to fund their current pipeline. As of Jan 2015, $30.7 million in cash/cash equivalents.

Social Media Q&A

Enrollment hasn't been delayed. Investigational funded trial. Lots of different parties working on their own pieces including FDA. They make estimations on when they will roll out, but they can't help it if things move more slowly due to all of the heads involved. Enrollment will move quickly when they can finally start.

Shareholder value: Focusing on trials so they can enter into licensing opportunities with other partners. For the time being, they've created multiple partnerships this year, and they're working on creating more but they can't discuss further.

Um... it's over? Yeah. That was useless. I tried to catch things as he talked, but I'm not a great transcriber. Basically, he just restated everything he's been saying for the past 3 months. He responded to 3 or 4 questions from Twitter. Annnnnnd. It's done.

Apparently I missed that they want 40-50 patients in the P2B trial. Not 10. That's from the google board.

He mentioned the devices, talked about what they do, and mentioned the partnership they recently announced. Not much hard info.

I want to go back over the presentation when I'm not moaning about being awake, but it sounded like a summary of press releases. I'm still pissed off that he only answered four investor questions in a span of five minutes. I went in assuming that would be the high point, but nope...